Boston Scientific stock falls as cyberattack prompts guidance cut and BTIG lowers price target

Boston Scientific stock (ISIN US10117L1017) was trading around USD 44.98 on the New York Stock Exchange as of September 8, 2026, after the company warned that a recent cyberattack will prevent it from meeting its previously issued guidance for the third quarter and full-year 2026, a setback that has drawn a swift reaction from analysts and investors.

Cyberattack forces Boston Scientific to withdraw 2026 guidance

According to Diamatix on September 9, 2026, Boston Scientific reported that a cybersecurity incident identified on August 25, 2026 disrupted key information technology systems and led to a global interruption of operations.

As Diamatix reports, the company now expects a material impact on its results for the third quarter and the full year 2026 and has said it is unlikely to meet its previously issued net sales growth and adjusted earnings per share guidance ranges for 2026.

In a market summary, WXXV News 25 noted on September 9, 2026 that Boston Scientific shares fell about 5.9 percent after the company said the network outage caused by the cybersecurity incident means it is unlikely to meet forecasts for sales and profit for the third quarter and full year 2026.

Previous 2026 guidance now withdrawn ahead of Q3 update

Before the cyberattack, Boston Scientific had provided detailed guidance for full-year 2026. As Simply Wall St summarizes, the company recently guided for full-year 2026 adjusted earnings between USD 3.28 and USD 3.32 per share, with expected sales growth of 5.5 percent to 6.5 percent.

For the third quarter of 2026 alone, Boston Scientific had projected adjusted earnings of USD 0.80 to USD 0.82 per share, according to Simply Wall St.

These guidance ranges are now off the table: Diamatix notes that Boston Scientific has stated it is unlikely to achieve its previously issued net sales growth and adjusted earnings per share guidance for the third quarter and full-year 2026 because of the disruption.

Analyst BTIG cuts price target but keeps Buy rating

The cyber incident and guidance withdrawal have already prompted a notable analyst reaction. On September 9, 2026, BTIG lowered its Boston Scientific stock price target from USD 60.00 to USD 56.00 while maintaining a Buy rating on the shares, according to MarketBeat.

As GuruFocus explains, BTIG maintained its Buy rating on Boston Scientific but reduced the price target by about 6.67 percent, from USD 60 to USD 56, reflecting a more cautious stance on near-term performance while still seeing upside.

BTIG’s new target of USD 56 implies roughly 24.4 percent potential upside from the company’s current share price level cited in the analyst report, per MarketBeat.

Consensus targets still well above current share price

Despite BTIG’s cut, the broader analyst community continues to see Boston Scientific stock as undervalued. Based on data compiled by MarketBeat, Boston Scientific has an average rating of Moderate Buy with a consensus 12-month price target of USD 71.46.

This consensus target of USD 71.46 stands significantly above the roughly USD 44.98 share price cited in recent valuation commentary, implying more than 50 percent upside if the stock were to reach the average target, according to figures highlighted by GuruFocus.

Another overview from Simply Wall St shows a current average one-year price target of about USD 76.48, with individual analyst estimates ranging from USD 55.00 on the low end to USD 106.00 on the high end.

Operational recovery and key risks after the cyber incident

While the cyber incident has clearly increased near-term earnings uncertainty, Boston Scientific is working to restore operations. As Diamatix reports, major distribution centers are now processing and shipping orders at or above normal operating levels, sterilization facilities are operational and manufacturing has resumed across most of the company’s global facilities.

The company’s update also indicated that product quality analyses had not identified impairment to device function and that a disruption affecting activations for remote monitoring of certain cardiac devices had been resolved, meaning activations can resume, according to Diamatix.

An additional clinical perspective from Omnicuris on September 9, 2026 notes that comprehensive internal product assessments confirmed no impairment to physical device integrity or software code and that rigorous quality audits verified complete product sterility, meaning healthcare providers can continue to use Boston Scientific implants and consumables without concern over manufacturing defects related to the incident.

Stock valuation and recent performance metrics

The guidance withdrawal and cyberattack have weighed on Boston Scientific stock performance. A recent performance snapshot from Simply Wall St cites a Boston Scientific share price of about USD 45.29, with analysts estimating an average one-year target of USD 76.48, suggesting the stock trades at a discount to perceived fair value.

In a separate options-focused analysis, Trefis notes on September 9, 2026 that Boston Scientific shares are trading near USD 45 and sit about 58 percent below their 52-week peak, highlighting how sharply the stock has pulled back from earlier highs.

That same analysis from Trefis illustrates the discount by pointing to an approximate USD 44.98 share price compared against a 52-week high around USD 108, underscoring the magnitude of the drawdown that long-term investors have experienced.

Next earnings update expected in late October

Investors will get more clarity on the financial impact of the cyberattack when Boston Scientific reports its third-quarter 2026 results. As summarized by Simply Wall St, the company plans to provide an updated outlook when it releases Q3 results, which market commentary currently expects around October 28, 2026.

Until that update arrives, the combination of withdrawn guidance, a significant recent share-price decline of around 58 percent relative to the 52-week high and mixed analyst reactions, including BTIG’s price-target cut, is likely to dominate the narrative for Boston Scientific stock.

Boston Scientific stock price and exchange reference

Boston Scientific stock is primarily listed on the New York Stock Exchange under the ticker BSX. Recent market data cited in analyst and valuation overviews place the shares around USD 44.98 to USD 45.29 as of September 8, 2026, with the stock trading well below the consensus 12-month analyst price target range between USD 55 and USD 106.

More news and analyses on Boston Scientific stock